Our findings are likely to be more generalisable than those of previous studies in cohorts offered the HPV vaccine opportunistically [26] and [27]. Vaccination status was self-reported which may have limited reliability 3 years post-vaccination. Around 10% of respondents did not know their vaccine status, and there was some variation between reported levels of vaccination in our sample and levels

recorded by the Primary Care Trusts in which the schools were located (data not reported). We were unable to validate individual-level vaccine status due to the PI3K Inhibitor Library mw need to assure anonymity. As estimates of the accuracy of self-reported HPV vaccine status vary, more research in this context is warranted [52] and [53]. The 10% of girls who responded ‘don’t know’ to the vaccine status question were similar in terms of demographic and behavioural risk factors to girls who were un/under-vaccinated (analyses not reported). We repeated our regression analyses including these girls in the un/under-vaccinated

GDC-0199 supplier group, and found very similar results to those reported here, suggesting that these girls were unlikely to be fully vaccinated. Our results suggest that un/under-vaccinated girls in England may be at disproportionately greater risk of cervical cancer due not only to their vaccine status, but also their low screening intentions. Efforts will be needed to ensure that un/under-vaccinated women understand the importance of cervical screening when they reach

the age that screening invitations begin. There is also an urgent need to understand ethnic inequalities in vaccination uptake. All authors declare no conflict of interest that may have influenced this work. JW conceptualised and designed the study. HB and JW collected and analysed the data for the study and all authors contributed to the interpretation Tolmetin and the writing of this paper and have approved the final draft. This study was funded as part of a larger project grant from Cancer Research UK (Grant reference A13254). “
“Streptococcus pneumoniae (S. pneumoniae) is responsible for a substantial burden of disease, accountable for approximately 1.6 million deaths annually worldwide [1]. In developed countries, the incidence of invasive pneumococcal disease (IPD) is between 8 and 75 cases per 100,000 individuals [2], with studies showing that most IPD is attributable to only 20–30 of the 94 pneumococcal serotypes [3]. Recent studies of serotypes involved in IPD compare pre- and post-vaccination periods to examine changes in serotype distribution potentially due to the use of the 7-valent pneumococcal conjugate vaccine (PCV7). The USA, and other countries subsequently, showed great reductions in IPD not limited to vaccine targeted groups [4].